The relationship between ERCC1 mRNA and Protein Expression and Prognosis from Adjuvant Cisplatin Chemotherapy in patients withⅠ-ⅢA NSCLC

DENG Qiu-hua; YANG Hai-hong; LIN Yong-ping; Zhao Mei-ling; Zhang Ya-lei; Xu xia

doi:10.3969/j.issn.1002-266X.2014.19.003

Abstract：Objective To detect the mRNA and protein expression of ERCC 1 in human non-small cell lung carcinoma (NSCLC), and the correlation between them,and to investigate its relationship with prognosis following post-operative adju-vant platinum chemotherapy .Methods:The expression of ERCC 1 protein was examined by immunohistochemistry ( IHC) , and the expression of ERCC1 mRNA was examined by RT-PCR.we had analyzed 212 patients with NSCLC who underwent post-operative adjuvant platinum chemotherapy .The relationship of ERCC1 with disease-free survival ( DFS) and overall survival (OS) was analyzed.Results: ERCC1 with mRNA low expression patients disease free survival was significantly prolonged compared with High expression patients (median DFS 25.9 vs 15.4 months, P <0.0001).Multivariate Cox re-gression analysis showed that clinical TNM stage (HR=2.936, P=0.022) were significant independent predictors of DFS for patients with lung cancer , but There was no significant difference between the DFS of low ERCC 1 protein expression and high ERCC1 protein expression(median DFS 21.5 νs 21.0 months,P =0.282).Multivariate Cox regression analysis showed that clinical TNM stage(HR=2.726, P=0.033)were significant independent predictors of DFS for patients with lung cancer.the expression of ERCC1 mRNA was negatively related to the expression of ERCC 1 protein.Conclusion: the patients of stage Ⅰ-ⅢA with low expression of ERCC 1 had a longer disease-free survival than those with high expression of ERCCl.ERCC1 mRNA low expression was in relation with better prognosis following Adjuvant Cisplatin Chemotherapy in Operable NSCLC .The expression of ERCC1 mRNA was more suitable than the expression of ERCC 1 protein as a prognos-tic factor and predictive marker for platinum-based chemotherapy in operable NSCLC .